01.14.22 -- Listen Now: CAR T Manufacturing Control, Genome Engineering of Hematopoietic Stem Cells, and more!
01/14/22 Life Science Leader Newsletter
Stay updated with breaking news from Steve Doares. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
01/14/22 Life Science Leader Newsletter
01/12/22 Clinical Leader Newsletter
CLLS earnings call for the period ending August 6, 2021.
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results March 04, 2021 16:42 ET | Source: Cellectis Inc. Cellectis Inc. New York, New York, UNITED STATES Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting Partner A...